178 related articles for article (PubMed ID: 37962334)
1. Isavuconazole use and TDM in real-world pediatric practice.
Fernández Ledesma B; Mendoza-Palomar N; Melendo Pérez S; Fernández-Polo A; Renedo Miró B; Pau Parra A; Luque Pardos S; Grau Cerrato S; Vima Bofarull J; Martín-Gómez MT; Pujol Jover M; Benítez-Carbante MI; Díaz de Heredia C; Soler-Palacin P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0082923. PubMed ID: 37962334
[TBL] [Abstract][Full Text] [Related]
2. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
Garcia-Vidal C
Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
[TBL] [Abstract][Full Text] [Related]
3. Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.
Zhang T; Shen Y; Feng S
Front Cell Infect Microbiol; 2022; 12():1049959. PubMed ID: 36530445
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
6. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
7. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
8. Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support.
Miller M; Kludjian G; Mohrien K; Morita K
Am J Health Syst Pharm; 2022 Jul; 79(15):1245-1249. PubMed ID: 35377411
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
Durand ML; Kitt TM; Song Y; Marty FM
Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
[TBL] [Abstract][Full Text] [Related]
10. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
13. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
[TBL] [Abstract][Full Text] [Related]
14. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
[TBL] [Abstract][Full Text] [Related]
15. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
Kovanda LL; Maher R; Hope WW
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis.
Höhl R; Bertram R; Kinzig M; Haarmeyer GS; Baumgärtel M; Geise A; Muschner D; Prosch D; Reger M; Naumann HT; Ficker JH; Kubitz J; Steinmann J; Sörgel F
Mycoses; 2022 Jul; 65(7):747-752. PubMed ID: 35535740
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
19. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
[TBL] [Abstract][Full Text] [Related]
20. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
